| Ytd | 11.46% | |
| 1y | -36.67% |
| Open | 1.15 | Prev Close | 1.14 | Low | 1.08 | High | 1.15 | Mkt Cap | 118.98M |
| Vol | 40.21K | Avg Vol | 90.41K | EPS | -0.48 | P/E | N/A | Forward P/E | N/A |
| Beta | 3.52 | Short Ratio | 0.37 | Inst. Own | 0.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.75 | 200-d Avg | 0.88 | 1yr Est | 3.00 |
CTOR News
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-mark
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwrig
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-mar
HIVE Digital Technologies Ltd (NASDAQ: HIVE) rose in pre-market trading due to its subsidiary's
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst c
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTO
New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-uni
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-univer
Citius Oncology, Inc. (NASDAQ: CTOR - Get Free Report)'s share price rose 0.6% during mid-day tradin
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b
Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The m
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncolo
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and f
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citiu
Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 mil
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distr
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinica
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LY
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f
Third international distribution agreement further advances global access strategy with major market
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPH
